- Home
- CX vs RPRX Comparison
CX vs RPRX Comparison
Compare CX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CX | RPRX |
|---|---|---|
| Founded | 1906 | 1996 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 16.4B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CX | RPRX |
|---|---|---|
| Price | $11.57 | $38.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $10.95 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 5.5M | 3.5M |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | 0.76% | ★ 2.28% |
| EPS Growth | ★ 231.88 | N/A |
| EPS | 0.09 | ★ 1.75 |
| Revenue | ★ $15,869,840,000.00 | $2,349,844,000.00 |
| Revenue This Year | $2.25 | $37.66 |
| Revenue Next Year | $5.11 | $2.34 |
| P/E Ratio | ★ $12.19 | $22.06 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $4.89 | $25.28 |
| 52 Week High | $12.04 | $41.24 |
Technical Indicators
Market Signals| Indicator | CX | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 49.75 |
| Support Level | $11.58 | $38.20 |
| Resistance Level | $12.04 | $39.46 |
| Average True Range (ATR) | 0.26 | 0.57 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 54.01 | 57.78 |
Price Performance
Historical ComparisonAbout CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.